Core Viewpoint - The successful initiation of China's first invasive brain-computer interface (BCI) clinical trial marks the country as the second globally, after the United States, to enter this phase of clinical testing [3][4]. Group 1: Clinical Trial Overview - The clinical trial is a collaborative effort involving the Chinese Academy of Sciences' Center for Excellence in Brain Science and Intelligence Technology, Fudan University Huashan Hospital, and related enterprises [3][4]. - The research team progressed from animal testing to human trials, ensuring the technology's maturity, safety, and functional effectiveness, achieving a breakthrough from laboratory to clinical application [3][4][5]. Group 2: Technical Innovations - The BCI system utilizes a minimally invasive "embedded" surgical method, requiring only a small recess in the skull rather than full craniotomy, which reduces recovery time and infection risks [7][8]. - The flexible neural electrodes developed are significantly smaller and more flexible than existing products, such as those from Neuralink, with a cross-sectional area only 1/7 to 1/5 of Neuralink's electrodes, minimizing tissue damage and inflammatory responses [7][8][9]. Group 3: Patient Experience and Outcomes - A 37-year-old male participant, who lost all four limbs due to an accident, successfully used the BCI to play chess and racing games, achieving a performance speed comparable to that of able-bodied individuals [3][9]. - After just 2-3 weeks of adaptive training, the participant was able to type, send messages, and play computer games, regaining a sense of "hand" functionality and reconnecting with the world [9][10]. Group 4: Future Prospects - The project team plans to enable the participant to control robotic arms for physical tasks such as grasping and holding objects, expanding his capabilities in daily life [10]. - The BCI system is expected to assist individuals with complete spinal cord injuries, upper limb amputations, and amyotrophic lateral sclerosis in regaining motor functions and improving their quality of life once it receives regulatory approval for market entry [10].